Literature DB >> 27002518

Economic Evaluations of Opioid Use Disorder Interventions.

Sean M Murphy1, Daniel Polsky2.   

Abstract

BACKGROUND: The economic costs associated with opioid misuse are immense. Effective interventions for opioid use disorders are available; however, given the scarce resources faced by substance use treatment providers and payers of all kinds, evidence of effectiveness is not always sufficient to encourage adoption of a given therapy-nor should it be. Economic evaluations can provide evidence that will help stakeholders efficiently allocate their resources.
OBJECTIVE: The purpose of this study was to review the literature on economic evaluations of opioid use disorder interventions.
METHODS: We performed a systematic review of the major electronic databases from inception until August 2015. A sensitive approach was used to ensure a comprehensive list of relevant articles. Given the quality of the existing reviews, we narrowed our search to studies published since 2007. The Drummond checklist was used to evaluate and categorize economic evaluation studies according to their quality.
RESULTS: A total of 98 articles were identified as potentially relevant to the current study. Of these 98 articles, half (n = 49) were included in this study. Six of the included articles were reviews. The remaining 43 articles reported economic evaluation studies of interventions for opioid use disorders. In general, the evidence on methadone maintenance therapy (MMT) supports previous findings that MMT is an economically advantageous opioid use disorder therapy. The economic literature comparing MMT with other opioid use disorder pharmacotherapies is limited, as is the literature on other forms of therapy.
CONCLUSION: With the possible exception of MMT, additional high-quality economic evaluations are needed in order to assess the relative value of existing opioid use disorder interventions.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27002518      PMCID: PMC5572804          DOI: 10.1007/s40273-016-0400-5

Source DB:  PubMed          Journal:  Pharmacoeconomics        ISSN: 1170-7690            Impact factor:   4.981


  60 in total

1.  What does the value of modern medicine say about the $50,000 per quality-adjusted life-year decision rule?

Authors:  R Scott Braithwaite; David O Meltzer; Joseph T King; Douglas Leslie; Mark S Roberts
Journal:  Med Care       Date:  2008-04       Impact factor: 2.983

2.  Cost-effectiveness of long-term outpatient buprenorphine-naloxone treatment for opioid dependence in primary care.

Authors:  Bruce R Schackman; Jared A Leff; Daniel Polsky; Brent A Moore; David A Fiellin
Journal:  J Gen Intern Med       Date:  2012-01-04       Impact factor: 5.128

3.  Relationship between buprenorphine adherence and health service utilization and costs among opioid dependent patients.

Authors:  Joseph Tkacz; Joseph Volpicelli; Hyong Un; Charles Ruetsch
Journal:  J Subst Abuse Treat       Date:  2013-11-12

4.  Cost-utility analysis of methadone maintenance treatment in Lithuania.

Authors:  Giedrius Vanagas; Zilvinas Padaiga; Eugenijus Bagdonas
Journal:  Medicina (Kaunas)       Date:  2010       Impact factor: 2.430

5.  Cost-effectiveness of diacetylmorphine versus methadone for chronic opioid dependence refractory to treatment.

Authors:  Bohdan Nosyk; Daphne P Guh; Nicholas J Bansback; Eugenia Oviedo-Joekes; Suzanne Brissette; David C Marsh; Evan Meikleham; Martin T Schechter; Aslam H Anis
Journal:  CMAJ       Date:  2012-03-12       Impact factor: 8.262

6.  Economic evaluation using decision analytical modelling: design, conduct, analysis, and reporting.

Authors:  Stavros Petrou; Alastair Gray
Journal:  BMJ       Date:  2011-04-11

7.  Cost-effectiveness of methadone maintenance therapy as HIV prevention in an Indonesian high-prevalence setting: a mathematical modeling study.

Authors:  Joost J G Wammes; Adiatma Y Siregar; Teddy Hidayat; Reynie P Raya; Reinout van Crevel; André J van der Ven; Rob Baltussen
Journal:  Int J Drug Policy       Date:  2012-08-10

Review 8.  Therapeutic opioids: a ten-year perspective on the complexities and complications of the escalating use, abuse, and nonmedical use of opioids.

Authors:  Laxmaiah Manchikanti; Angelie Singh
Journal:  Pain Physician       Date:  2008-03       Impact factor: 4.965

9.  Opioid drug utilization and cost outcomes associated with the use of buprenorphine-naloxone in patients with a history of prescription opioid use.

Authors:  Aman Deep Kaur; Angela McQueen; Saira Jan
Journal:  J Manag Care Pharm       Date:  2008-03

Review 10.  Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence.

Authors:  Richard P Mattick; Courtney Breen; Jo Kimber; Marina Davoli
Journal:  Cochrane Database Syst Rev       Date:  2009-07-08
View more
  29 in total

1.  Impact Of Long-Term Buprenorphine Treatment On Adverse Health Care Outcomes In Medicaid.

Authors:  Hillary Samples; Arthur Robin Williams; Stephen Crystal; Mark Olfson
Journal:  Health Aff (Millwood)       Date:  2020-05       Impact factor: 6.301

2.  Prescribing decisions at buprenorphine treatment initiation: Do they matter for treatment discontinuation and adverse opioid-related events?

Authors:  Angélica Meinhofer; Arthur Robin Williams; Phyllis Johnson; Bruce R Schackman; Yuhua Bao
Journal:  J Subst Abuse Treat       Date:  2019-07-24

3.  Cost-effectiveness of expanding the capacity of opioid agonist treatment in Ukraine: dynamic modeling analysis.

Authors:  Olga Morozova; Forrest W Crawford; Ted Cohen; A David Paltiel; Frederick L Altice
Journal:  Addiction       Date:  2019-10-29       Impact factor: 6.526

4.  The costs of crime during and after publicly funded treatment for opioid use disorders: a population-level study for the state of California.

Authors:  Emanuel Krebs; Darren Urada; Elizabeth Evans; David Huang; Yih-Ing Hser; Bohdan Nosyk
Journal:  Addiction       Date:  2017-02-06       Impact factor: 6.526

5.  Cost-Effectiveness of Buprenorphine-Naloxone Versus Extended-Release Naltrexone to Prevent Opioid Relapse.

Authors:  Sean M Murphy; Kathryn E McCollister; Jared A Leff; Xuan Yang; Philip J Jeng; Joshua D Lee; Edward V Nunes; Patricia Novo; John Rotrosen; Bruce R Schackman
Journal:  Ann Intern Med       Date:  2018-12-18       Impact factor: 25.391

6.  The Value of Shorter Initial Opioid Prescriptions: A Simulation Evaluation.

Authors:  Margrét V Bjarnadóttir; David R Anderson; Kislaya Prasad; Ritu Agarwal; D Alan Nelson
Journal:  Pharmacoeconomics       Date:  2020-01       Impact factor: 4.981

7.  Cost-effectiveness of emergency department-initiated treatment for opioid dependence.

Authors:  Susan H Busch; David A Fiellin; Marek C Chawarski; Patricia H Owens; Michael V Pantalon; Kathryn Hawk; Steven L Bernstein; Patrick G O'Connor; Gail D'Onofrio
Journal:  Addiction       Date:  2017-08-16       Impact factor: 6.526

8.  Legislators' Sources of Behavioral Health Research and Preferences for Dissemination: Variations by Political Party.

Authors:  Jonathan Purtle; Elizabeth A Dodson; Katherine Nelson; Zachary F Meisel; Ross C Brownson
Journal:  Psychiatr Serv       Date:  2018-07-09       Impact factor: 3.084

9.  Risk factors for discontinuation of buprenorphine treatment for opioid use disorders in a multi-state sample of Medicaid enrollees.

Authors:  Hillary Samples; Arthur Robin Williams; Mark Olfson; Stephen Crystal
Journal:  J Subst Abuse Treat       Date:  2018-09-07

10.  Cost of pharmacotherapy for opioid use disorders following inpatient detoxification.

Authors:  Kathryn E McCollister; Jared A Leff; Xuan Yang; Joshua D Lee; Edward V Nunes; Patricia Novo; John Rotrosen; Bruce R Schackman; Sean M Murphy
Journal:  Am J Manag Care       Date:  2018-11       Impact factor: 2.229

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.